C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91% Market Closed
Market Cap: 245B KRW
Have any thoughts about
Cellivery Therapeutics Inc?
Write Note

Cellivery Therapeutics Inc
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cellivery Therapeutics Inc
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Short-Term Investments
â‚©557.1B
CAGR 3-Years
10%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Short-Term Investments
â‚©1.6B
CAGR 3-Years
-39%
CAGR 5-Years
26%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Short-Term Investments
â‚©40B
CAGR 3-Years
-17%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Short-Term Investments
â‚©18B
CAGR 3-Years
-22%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Short-Term Investments
â‚©77.6B
CAGR 3-Years
-7%
CAGR 5-Years
23%
CAGR 10-Years
18%
No Stocks Found

Cellivery Therapeutics Inc
Glance View

Market Cap
244.9B KRW
Industry
Life Sciences Tools & Services

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Intrinsic Value
1 499.84 KRW
Overvaluation 78%
Intrinsic Value
Price
C

See Also

Back to Top